Prognostic Factors in IDH-Mutant Gliomas

IDH-mutant gliomas constitute a distinct category of diffuse gliomas that harbour mutations in isocitrate dehydrogenase (IDH) 1 or 2 and typically affect younger adults. These tumours generally confer a more favourable prognosis than their IDH-wildtype counterparts, but survival outcomes remain highly variable and are influenced by a constellation of clinical, radiological and molecular features. Clinical factors such as patient age and functional status at diagnosis, often measured by scales like the Karnofsky Performance Status, remain key determinants of outcome. Radiological parameters, including tumour volume, contrast enhancement and extent of resection, further modulate prognosis. At the molecular level, co-occurring alterations such as 1p/19q codeletion in oligodendrogliomas, global DNA methylation patterns and epigenetic markers such as MGMT promoter methylation have been shown to refine risk stratification. Emerging evidence also highlights the prognostic significance of genetic events, notably homozygous deletion of the CDKN2A locus, aberrations in cyclin-dependent kinase pathways and the overall tumour mutational burden. Integrative histomolecular grading schemes that combine tumour grade, molecular signature and patient-specific factors have improved the precision of survival estimates and informed therapeutic choices. Such multifactorial models support individualised treatment planning, including decisions on the timing of radiotherapy, the intensity of chemotherapy and the incorporation of targeted agents such as IDH inhibitors. Ongoing studies aim to validate these parameters prospectively and to harmonise grading algorithms in anticipation of future revisions to international classification frameworks. Overall, a deeper understanding of prognostic determinants is critical for optimising outcomes and guiding the next generation of personalised interventions in IDH-mutant glioma.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Prognostic Factors in IDH-Mutant Gliomas publication trend

The graph below shows the total number of articles in prognostic factors in idh-mutant gliomas across all publications each year (not limited to Nature Index journals).

Technical terms

IDH mutation: Somatic alteration in isocitrate dehydrogenase 1 or 2 genes that defines a molecular subset of diffuse glioma with distinct biology and survival.

CDKN2A homozygous deletion: Loss of both copies of the cell cycle regulator gene CDKN2A, associated with aggressive tumour behaviour.

Global DNA methylation: Epigenetic quantification of methyl groups across the genome, often assessed by LINE-1 assays to reflect overall methylation status.

1p/19q codeletion: Concurrent loss of chromosomal arms 1p and 19q, characteristic of oligodendroglioma and linked to treatment sensitivity and improved prognosis.

Karnofsky Performance Status: A standardised scale measuring patient functional capacity and ability to perform daily activities, predictive of clinical outcome.

Immunohistochemistry (IHC): A laboratory technique that uses antibodies to detect specific proteins in tissue sections, guiding molecular diagnostics and prognostication.

References

1. The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?. Neuro-Oncology (2024).
2. Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma. Acta Neuropathologica (2024).
3. P16 immunohistochemistry is a sensitive and specific surrogate marker for CDKN2A homozygous deletion in gliomas. Acta Neuropathologica Communications (2023).